5-ethyl-1-naphthol | 61982-95-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-ethyl-1-naphthol
• 英文别名: 5-Ethylnaphthalen-1-ol
• CAS: 61982-95-4
• 化学式: C₁₂H₁₂O
• 分子量: 172.227
• InChiKey: QWAWNXODWGJFPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-ethyl-1-naphthol 在 potassium carbonate 作用下， 以 水 为溶剂， 反应 5.08h， 生成 4-ethyl-17-hydroxy-16,17-dihydro-11,15-dioxacyclopenta[a]phenanthren-12-one
  参考文献：
  名称：

  Antitumor Agents. 254. Synthesis and Biological Evaluation of Novel Neo-tanshinlactone Analogues as Potent Anti-Breast Cancer Agents

  摘要：

  In our previous study, neo-tanshinlactone ( 1) showed potent and selective anti-breast cancer activity. To explore the SAR of 1, nine analogues (15-18, 24-28) were designed and synthesized. Together with 1 and tamoxifen (TAM), all newly synthesized compounds and some intermediates were evaluated for in vitro anticancer activity against several human tumor cell lines. Compounds without a ring D did not show promising activity, while compounds with a methylated furan ring D showed better activity than those with unsubstituted furan or hydroxy-dihydrofuran rings. Among all newly synthesized compounds, compound 15 with an ethyl group at the 4-position showed the best activity and selectivity with ED50 values of 0.45 and 0.18 mu g/mL against MCF-7 and ZR-75-1 (ER+) and 13.5 and 10.0 mu g/mL against MDA MB-231 and HS 587-1 (ER-), respectively. Furthermore, 15 also showed potent activity against SK-BR-3 (ER-, HER2+) with an ED50 value of 0.10 mu g/mL. Our preliminary SAR studies showed that a methylated furan ring D and the C-4 substituent in ring A are critical for anti-breast cancer activity. Further development of 1 and 15 as anti-breast cancer drug candidates is warranted.

  DOI：

  10.1021/jm060184d
• 作为产物：
  描述：

  5-Ethyl-1-methoxynaphthalin 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以75%的产率得到5-ethyl-1-naphthol
  参考文献：
  名称：

  [EN] NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS
  [FR] PUISSANTS ANTICANCEREUX SELECTIFS (CANCER DU SEIN) A BASE DE NEO-TANSHINLACTONE ET ANALOGUES

  摘要：

  化合物的公式（I-II）被描述：以及使用这些化合物治疗癌症的方法和药物配方。

  公开号：

  WO2005087225A1

文献信息

• [EN] NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS<br/>[FR] PUISSANTS ANTICANCEREUX SELECTIFS (CANCER DU SEIN) A BASE DE NEO-TANSHINLACTONE ET ANALOGUES
  申请人：UNIV NORTH CAROLINA

  公开号：WO2005087225A1

  公开（公告）日：2005-09-22

  Compounds of Formulae (I-II) are described : along with methods of using such compounds for the treatment of cancer and pharmeutical formulations thereof.

  化合物的公式（I-II）被描述：以及使用这些化合物治疗癌症的方法和药物配方。
• Oxidation with Fremy's salt—VIII
  作者：H. Ishii、T. Hanaoka、T. Asaka、Y. Harada、N. Ikeda

  DOI：10.1016/0040-4020(76)80108-1

  日期：1976.1

  It has been shown by a series of experiments on 5-alkyl, 5-halo-, and other 5-substituted 1-naphthol derivatives that the product ratio of the ortho- and para-naphthoquinones formed on oxidation with Fremy's salt is controlled by the bulkiness of the C5-substituent.

  在5-烷基，5-卤代和其他5-取代的1-萘酚衍生物上进行的一系列实验表明，用Fremy's盐氧化形成的邻萘和对萘萘醌的产物比率受C 5-取代基的体积大。
• Process For Producing Phosphonitrilic Acid Ester
  申请人：Kuwata Kotaro

  公开号：US20080091050A1

  公开（公告）日：2008-04-17

  A process for producing a cyclic and/or linear phosphonitrilic acid ester from a cyclic and/or linear phosphonitrile dichloride is provided, wherein the reaction time is shorter and the content of monochloro phosphazenes is very small. When phosphonitrile dichloride is reacted with a metal arylolate and/or a metal alcoholate in the presence of a reaction solvent, a metal arylolate and/or a metal alcoholate composed of at least two different metals having different ionization energies is used and also a specific compound is used as a catalyst.

  解决的问题：提供一种从环状和/或线性磷酸腈二氯化物制备环状和/或线性磷氮酸酯的方法，其中反应时间较短，单氯磷氮烷的含量非常小。 解决方案：当磷酸腈二氯化物与金属芳酚醇盐和/或金属醇盐在反应溶剂存在下反应时，使用由至少两种具有不同电离能的金属组成的金属芳酚醇盐和/或金属醇盐，并且还使用特定化合物作为催化剂。
• NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS
  申请人：Lee Kuo-Hsiung

  公开号：US20090118356A1

  公开（公告）日：2009-05-07

  Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.

  描述了I-II式化合物，以及使用这些化合物治疗癌症和制备制药配方的方法。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。